Introduction {#sec1}
============

*Proteus* spp. is widely spread in the environment. It may occur in water, soil, manure or sewage, and it is also a component of human and animal gastrointestinal tract microbiome ([@bib15]; [@bib6]). In the current taxonomy of *Proteus* genus, eight species are included: *Proteus mirabilis*, *Proteus vulgaris*, *Proteus penneri*, *Proteus hauseri*, *Proteus cibarius*, *Proteus columbae*, *Proteus incostans*, and *Proteus terrae. P. mirabilis* is the most common species of this genus isolated from human infections ([@bib16]; [@bib2]).

In addition to be a leading cause of urinary tract infections (UTI) and chronic wound infections ([@bib7]), *P. mirabilis* can also cause bloodstream infections. *P. mirabilis* is found in 1--3% of all BSIs ([@bib19]). Other *Proteus* species are rare in BSIs and occur at rates of less than 0.1 per 100 000 ([@bib12]).

The most common source of bacteria in BSIs caused by *P. mirabilis* is the urinary tract (UT) ([@bib21]). According to [@bib21] and [@bib9], UT is a source of 47.6--52.8% BSIs caused by *P. mirabilis* ([@bib21]; [@bib9]).

Among infectious diseases, BSIs are a major cause of mortality worldwide ([@bib12]). [@bib7] found that mortality rate attributable to *P. mirabilis* BSIs is higher in BSIs cases caused by strains with extended spectrum beta-lactamases (ESBL). The presence of beta-lactamases may seriously limit BSIs treatment options. *Proteus* spp. is inherently resistant to polymyxins that are used, beside carbapenems, in empiric treatments of BSIs caused by Gram-negative bacilli. *P. mirabilis* might produce likewise, the AmpC-type cephalosporinases and carbapenemases (KPC) ([@bib20]; [@bib5]).

The aims of this study were: a) retrospective susceptibility analysis of *Proteus* spp. strains isolated from BSIs, b) the similarity evaluation of 26 *P. mirabilis* strains isolated from clinical samples collected from randomly chosen 11 hospital patients.

Experimental {#sec2}
============

Materials and Methods {#sec3}
---------------------

**Identification and susceptibility testing of clinical *Proteus* spp. strains.** *Proteus* spp. strains were isolated from 2009 to 2017 from patients of the Antoni Jurasz University Hospital No 1 in Bydgoszcz, Poland. Basic information, i.e., age, sex of patients, and the samples collected were determined using laboratory data. Details, i.e.: short-term (14 days) mortality after bacteremia, length of stay, period from admission to the hospital to the onset of *Proteus* spp. bacteremia, presence of urinal or central venal catheters, the previous surgery, and additional diseases were determined by using electronic administrative data. We did not find any detailed information about 15 patients hospitalized in 2009--2010; they were excluded from epidemiological analyzes.

The strains were identified at the Department of Microbiology: a) between 2009 and 2011 the identification was based on colony's morphology and the results of biochemical reactions (API 32E, BioMériuex), b) between 2011 and 2014 -- on biochemical reaction results included in the VITEK GN cards (BioMériuex), and c) since 2014 -- by using MALDI-TOF MS technique (Microflex, Bruker).

Susceptibility of *Proteus* spp. strains was examined: in 2009 and 2010 by using the disk diffusion method and interpreted in accordance with the Clinical and Laboratory Standard Institute ([@bib3]) recommendation; since 2011 -- using VITEK AST cards (BioMériuex) and interpreted according to the European Committee on Antimicrobial Susceptibility Testing ([@bib8]). The meropenem susceptibility was evaluated since 2016.

Extended-spectrum beta-lactamases (ESBLs) were examined according to the CLSI recommendation by using the double disk synergic test (DDST).

Primary bacteremia was defined as the bacteremia for which no source of infection was documented. Bacteremia was defined as secondary when laboratory examination showed infection by the same microorganism at a distant site in the same time or up to three days earlier.

Until the investigation, the selected strains were stored in BHI with 20.0% glycerol at 70°C.

**Genetic similarity and phenotypic characterization of *P. mirabilis* strains.** A detailed analysis was performed for 26 strains isolated from 11 (A-K) randomly chosen patients with *P. mirabilis* bacteremia. Strains were isolated from three different samples from four patients, and from two different samples -- from seven patients. Two patients had urethral catheters, and one -- peripheral venous catheter.

**Susceptibility patterns.** The susceptibility assays of *P. mirabilis* strains were done using the diffusion method according to CLSI recommendation, including the following antibiotics in discs (Emapol): trimethoprim TRM (5 μg), norfloxacin NOR (10 μg), netilmicin NET (30 μg), tobramicin TOB (10 μg), ticarcilin TIC (75 μg), amikacin AMK (30 μg), imipenem IMP (10 μg), ciprofloxacin CIP (5 μg), cephoperazone CEP (75 μg), piperacillin PIP (100 μg), ampicillin AM (10 μg), ticarcillin with clavulanic acid TIM (85 μg), cefuroxime CXM (30 μg), ampicillin with sulbactam UNA (20 μg), gentamicin GEN (10 μg). All results were interpreted according to [@bib8].

**Biofilm formation.** Biofilm formation by 26 *P. mirabilis* strains was evaluated based on the method described previously by [@bib10]. The method is based on the measurement of absorbance of formazan (dissolution product of 2,3,5-triphenyl-tetrazolium chloride, TTC; Avantor; λ = 470 nm) (BioTek; Synergy HT Multi-detection; KC4 program). The assay was done in three independent repetitions. Two reference strains from the American Type Culture Collection (ATCC): *Staphylococcus aureus* ATCC 6538 (strong biofilm former) and *Escherichia coli* ATCC 35218 (weak biofilm former) were used as the positive and negative control, respectively.

The A value was calculated based on the average (x) and threefold standard deviation (SD) of blank absorbance. The strains which had an absorbance above the A value were classified as being able to biofilm formation. All strains with an absorbance in the range between A and 2 × A were classified as weak biofilm formers (W), in the range between 2 × A and 4 × A -- as moderate biofilm formers (M), and above 4 × A -- as strong biofilm formers (S).

**Dienes phenomenon testing.** To examine the Dienes phenomenon of *P. mirabilis* strains, single colonies, previously cultured on MacConkey Agar, were inoculated as points on blood agar plates (Oxoid). The strains isolated from the same patient were inoculated on one plate. Plates were incubated at 37°C. After 24 hours, demarcation lines between strains were observed. When strains were non-identical, colonies were separated by the demarcation line (0.5--2 mm wide) (Fig. [1A](#fig1){ref-type="fig"}). When strains were identical -- there was any demarcation line ([@bib17]) (Fig. [1B](#fig1){ref-type="fig"}).

![The Dienes phenomenon: A) non-identical strains, B) identical strains.](pjm-67-4-471-g001){#fig1}

**Genetic similarity of *P. mirabilis* strains.** Genetic similarity of *Proteus* spp. strains was evaluated by pulsed field gel electrophoresis (PFGE) using *Sfi*I (Fermentas) restriction enzyme cleavage, as previously described by [@bib17] with own modifications, described by [@bib11]). Comparative analysis was performed using the Quantitative One software according to Dice.

**Statistical analysis.** Statistical analysis was performed using Statistica 12.5 PL (StatSoft) software. The confidence interval for all tests was *α* = 0.05. To compare variables, the *chi*^2^ test with Yates' correction was used, if necessary.

Results {#sec4}
=======

***Proteus* spp. blood stream infections.** In the examined time period (2009--2017), BSIs were found in 3956 cases in 2829 patients. BSIs caused by *Proteus* spp. were confirmed in 98 cases (2.5%) in 97 patients (3.4%). In one female patient, secondary urinary tract bacteremia was recognized two times with a six-months interval between symptoms (Table [II](#tblII){ref-type="table"}).

*Proteus* spp. bacteremia was caused by *P. vulgaris* in five (5.2%) patients and by *P. mirabilis* in other patients (94.8%). In *P. vulgaris* bacteremia cases, four strains were isolated only from blood samples. One *P. vulgaris* bacteremia was related with a previous isolation of the same species strain from a chronic wound.

Median age for all patients with *Proteus* spp. bacteremia was 71 years. We found that 14-day mortality ratio of *Proteus* spp. bacteremia was 28.9%. None of *P. vulgaris* strain was related with short-term mortality. We observed that elderly patients have a higher risk of mortality (Table [I](#tblI){ref-type="table"}).

###### 

Demographic and clinical parameters of patients with Proteus spp. BSIs (n = 83).

![](pjm-67-4-471-t001)

  Variable                                                                        Death in 14 days (n = 24)   Survival (n = 59)   *p*-value[\*](#FNt1){ref-type="fn"}   
  ------------------------------------------------------------------------------- --------------------------- ------------------- ------------------------------------- --------
  Age (years), median (min-max)                                                   77.5 (55--94)               67.0 (12--88)       0.0025[\*\*](#FNt2){ref-type="fn"}    
  Sex                                                                             Men, No. (%)                13 (54.2)           33 (55.9)                             0.9229
  Women, No. (%)                                                                  11 (45.8)                   26 (44.1)                                                 
  Length of stay in hospital (days), median (min-max)                             19.5 (1--139)               38 (5--406)         0.0142[\*\*](#FNt2){ref-type="fn"}    
  Length of stay in hospital before *Proteus* spp. BSI (days), median (min-max)   9.5 (0--138)                7.5 (0--380)        1.0000[\*\*](#FNt2){ref-type="fn"}    
  Primary bacteremia, No. (%)                                                     11 (45.8)                   23 (39.0)           0.7420                                
  Secondary bacteremia, No. (%)                                                   13 (54.2)                   36 (61.0)                                                 
  Adequate empiric antibiotic therapy, No. (%)                                    16 (66.7)                   43 (72.9)           0.7648                                
  More than one strain in blood culture, No. (%)                                  9 (37.5)                    20 (34.0)           0.9537                                
  ESBL *Proteus* spp., No. (%)                                                    4 (16.7)                    11 (18.6)           0.9185                                
  Predisposing factors                                                            Urinal catheter, No. (%)    18 (75.0)           44 (67.8)                             0.8117
  Central Venus Catheter, No. (%)                                                 15 (62.5)                   28 (47.5)           0.3168                                
  Diabetes, No. (%)                                                               7 (29.2)                    10 (16.9)           0.3419                                
  Hospitalization during past half year, No. (%)                                  13 (54.2)                   25 (42.4)           0.4625                                
  Cancer, No. (%)                                                                 3 (12.5)                    4 (6.8)             0.6784                                
  Surgery during past half year, No. (%)                                          9 (37.5)                    33 (55.9)           0.2003                                
  Cardio-vascular diseases, No. (%)                                               15 (62.5)                   23 (39.0)           0.0879                                
  Chronic wounds, No. (%)                                                         7 (29.2)                    13 (22.0)           0.6849                                

*Chi*^2^ test,

U Mann-Whitney test

During the period analyzed, the most commonly used antibiotic for empiric therapy of BSIs was imipenem. Amongst 16 patients treated with imipenem, three (20.0%) of them died within 14 days. All *P. mirabilis* strains isolated from blood samples of these patients were susceptible to imipenem. Piperacillin with tazobactam was used in 15 cases of BSIs, and ceftriaxone -- in 13 cases. The 14-days mortality rate for piperacillin with tazobactam was 26.7%, and for ceftriaxone -- 44.0%.

Primary bacteremia was reported in 40 (40.8%) cases. The source of *P. mirabilis* secondary bacteremia was confirmed in 58 (59.2%) cases. In patients with secondary bacteremia, the main source of infection was the urinary tract (27; 46.6%), wounds of skin or soft tissues (14; 24.1%). In nine (9.2%) cases, *Proteus* spp. bacteremia occurred three days prior to isolation of the same bacterial species from wound swab, and in seven (7.1%) -- from urine samples (Table [II](#tblII){ref-type="table"}). One or more weeks after *P. mirabilis* bacteremia, strains of the same species were isolated from wound swabs (11; 11.2%), central venous catheter samples (5; 5.1%) and urine collected by a catheter (5; 5.1%).

###### 

The strains isolated from patients with *P. mirabilis* (n = 93) and *P. vulgaris* (n = 5) bacteremia.

![](pjm-67-4-471-t002)

  Year    spp. bacteremia *Protteus*   Secondary *Proteus* spp. bacteremia   Isolation of *Proteus* spp. not related directly to bacteremia                                                         
  ------- ---------------------------- ------------------------------------- ---------------------------------------------------------------- --- ---- --- --- --- --- --- --- --- --- ---- --- --- ---
  2009    12                           8 (66.7%)                             7                                                                1   0    0   0   1   0   2   0   0   0   1    1   0   0
  2010    12                           8 (66.7%)                             4                                                                0   2    2   0   0   2   0   0   0   0   4    1   2   0
  2011    7                            4 (57.1%)                             1                                                                0   2    0   1   0   2   0   1   1   0   0    1   0   0
  2012    4                            4 (100.0%)                            1                                                                1   1    1   0   0   0   1   0   0   0   0    0   1   0
  2013    14                           8 (57.1%)                             2                                                                2   2    2   0   3   2   1   0   0   0   2    0   1   1
  2014    14                           9 (64.3%)                             5                                                                0   3    1   0   0   2   1   0   0   1   0    0   0   1
  2015    9                            4 (44.4%)                             1                                                                1   2    0   0   0   0   0   0   0   1   1    1   0   0
  2016    15                           8 (53.3%)                             5                                                                1   1    1   0   0   1   1   0   0   1   1    0   0   0
  2017    11                           5 (45.5%)                             1                                                                2   1    0   1   0   0   1   0   0   2   2    1   1   0
  Total   98                           58 (59.2%)                            27                                                               8   14   7   2   4   9   7   1   1   5   11   5   5   2

All *Proteus* spp. strains isolated in 2016 and 2017 (n = 26) were susceptible to meropenem. Most strains were susceptible to piperacillin with tazobactam (95.9%), ceftazidime (87.8%) and amikacin (86.7%) (Table [III](#tblIII){ref-type="table"}). More than half of the strains examined (51.0%) were resistant to co-trimoxazole. Resistance to ciprofloxacin was reported in 30 (30.6%) strains. All 40 strains isolated from primary bacteremia cases were susceptible to piperacillin with tazobactam. No significant differences in the antimicrobial susceptibility of strains isolated from primary and secondary bacteremia were found (Table [III](#tblIII){ref-type="table"}).

###### 

Antibacterial agents (Aas) susceptibility of *Proteus* spp. strains (n = 98) isolated from bacteremia.

![](pjm-67-4-471-t003)

  Aas   Primary bacteremia Aas susceptibility   *p*[\*](#FNt3){ref-type="fn"}   Secondary bacteremia Aas susceptibility   Total Aas susceptibility                                                                                         
  ----- --------------------------------------- ------------------------------- ----------------------------------------- -------------------------- ---- ------ -------- ---- ------ ---- ------ ---- ------ ---- ------ ---- ------ ---- ------
  AMC   9                                       22.5                            24                                        60.0                       7    17.5   0.4588   16   27.6   28   48.3   14   24.1   25   25.5   52   53.1   21   21.4
  TZP   40                                      100.0                           0                                         0.0                        0    0.0    0.1316   54   93.1   0    0.0    4    6.9    94   95.9   0    0.0    4    4.1
  CMX   28                                      70.0                            0                                         0.0                        12   30.0   0.6037   45   77.6   0    0.0    13   22.4   73   74.5   0    0.0    25   25.5
  CTX   31                                      77.5                            0                                         0.0                        9    22.5   0.3393   46   79.3   0    0.0    12   20.7   77   78.6   0    0.0    21   21.4
  CAZ   35                                      87.5                            2                                         5.0                        3    7.5    0.1697   51   87.9   0    0.0    7    12.1   86   87.8   2    2.0    10   10.2
  FEP   32                                      80.0                            2                                         5.0                        6    15.0   0.4254   48   82.8   4    6.9    6    10.3   80   81.6   6    6.1    12   12.2
  IMP   30                                      75.0                            8                                         20.0                       2    5.0    0.6062   49   84.5   8    13.8   1    1.7    79   80.6   16   16.3   3    3.1
  GEN   29                                      72.5                            1                                         2.5                        10   25.0   0.3662   46   79.3   1    1.7    11   19.0   75   76.5   2    2.0    21   21.4
  AMK   33                                      82.5                            3                                         7.5                        4    10.0   0.6311   52   89.7   4    6.9    2    3.4    85   86.7   7    7.1    6    6.1
  CIP   24                                      60.0                            1                                         2.5                        15   37.5   0.4336   38   65.5   5    8.6    15   25.9   62   63.3   6    6.1    30   30.6
  SXT   20                                      50.0                            0                                         0.0                        20   50.0   0.3165   28   48.3   0    0.0    30   51.7   48   49.0   0    0.0    50   51.0

*chi*^2^ test -- differences in the susceptibility of *Proteus* spp. strains isolated from primary and secondary bacteremia S -- susceptible, I -- intermediate, R -- resistant, AMC -- amoxicillin + clavulanic acid, TZP -- piperacillin with tazobactam, CXM -- cefuroxime, CTX -- cefotaxime, CAZ -- ceftazidime, FEP -- cefepime, IMP -- imipenem, GEN -- gentamicin, AMK -- amikacin, CIP -- ciprofloxacin, SXT -- co-trimoxazole

ESBLs were found in 18 (18.3%) out of 98 *Proteus* spp. strains. Among all ESBL positive strains, 6 (33.3%) were isolated in 2016, and 5 (27.8%) in 2017. None of the *P. vulgaris* strains produced ESBLs.

We compared the antimicrobial drugs susceptibility of ESBLs-positive (ESBLs(+)) and ESBLs-negative (ESBLs(--)) strains using the *chi*^2^ test (Fig. [2](#fig2){ref-type="fig"}). Among the ESBLs(--) strains, all (n = 80) were susceptible to piperacillin with tazobactam. The ESBLs(+) strains were more resistant to all penicillins tested with beta-lactamases inhibitors and cephalosporins. Among the ESBLs(+) strains, more strains were non-susceptible to ciprofloxacin and co-trimoxazole than among ESBLs(--) bacteria (Fig. [2](#fig2){ref-type="fig"}).

![Antibiotic susceptibility of ESBLs(+) and ESBLs(--) *Proteus* spp. strains (n = 98) isolated from bacteremia; *p*-value of *chi*^2^ testing between susceptible and non-susceptible (resistant and intermediate) strains; abbreviations of antibiotic names (see Table [III](#tblIII){ref-type="table"}).](pjm-67-4-471-g002){#fig2}

**Susceptibility patterns.** The susceptibility patterns of isolates from different specimens of the same patient were similar, except of the isolate B3 that was genetically different from B1 and B2 and was more resistant to antibiotics than other two isolates collected from the same patient. Isolate J2, collected from urine four days before the bacteremia, were resistant to trimethoprim while J1 were susceptible to this antibiotic (Table [IV](#tblIV){ref-type="table"}).

###### 

Genetic similarity of *P. mirabilis* isolates (n = 26).

![](pjm-67-4-471-t004)

  --
  --

ESBLs were detected in five (19.2%) *P. mirabilis* isolates from two patients (D and G), treated in the Intensive Care Unit (G) and the Cardiology Department (D). Isolates D1, D2, G1, G2 and G3 had the same DNA profiles.

**Biofilm formation.** The A value was equal to 0.0654, based on the formazan absorbance of blank sample. The mean values (± SD) of absorbance recorded for biofilms formed by the references strains, were as follows: for *E. coli* ATCC 35218 -- 0.1031 ± 0.01, and for *S. aureus* ATCC 6538 -- 0.6931 ± 0.03. The results obtained for clinical *P. mirabilis* strains were shown in Table [IV](#tblIV){ref-type="table"}.

Weak biofilms were formed by 17 (65.4%) isolates, moderate biofilms by four (15.4%), and strong by five (19.2%) isolates. Most of the strains (8; 72.7%) isolated from blood samples formed weak biofilms. Two of three isolates collected from chronic wounds prior to bacteremia were able to form stronger biofilms than strains collected from blood samples. Two isolates from urine samples of catheterized patients formed moderate and strong biofilms, while isolates cultured from blood sample -- weak biofilms. The isolates from venal catheters formed weak biofilms, similarly to isolates from blood samples.

**Dienes phenomenon results.** We found demarcation lines between strains J1 and J2, B1 and B3, and B2 and B3 (Table [IV](#tblIV){ref-type="table"}). Those strains were not genetically identical. Strain J1, from urine collected by a catheter, formed a stronger biofilm than J2 cultured from the blood sample. The B3 strain, cultured from the bedsore swab sample, formed a strong biofilm, in contrast to B1 and B2 isolates that formed a weak biofilm.

**Genetic similarity of *P. mirabilis* isolates.** Using PFGE we found that isolates collected from different clinical specimens were identical in 10 of 11 patients (Table [IV](#tblIV){ref-type="table"}). In five patients (K, G, H, E, and J), the same strains were found in other localizations before the bacteremia was confirmed.

Strains J1 and J2, isolated from patient J, were genetically different and formed biofilms with various capacity, but they presented similar susceptibility patterns. The J2 strain was isolated from urine sample four days before J1 was cultured from blood sample.

Two strains, B1 and B2, were genetically identical as it was shown by their macrorestriction profiles. They formed weak biofilms and had the same susceptibility toward antibiotics. Strain B3, isolated from chronic wound swab nine days after confirmation of *P. mirabilis* bacteremia, was similar to B1 and B2, but it formed a strong biofilm and was resistant to higher number of the antibiotics tested than B1 and B2 isolates.

Discussion {#sec5}
==========

The *P. mirabilis* is isolated from 1% to 3% of all BSIs ([@bib13]; [@bib18]). Our study confirms these data. We also observed *Proteus* spp. BSIs in 2.5% of all BSIs investigated. Among *Enterobacterales*, *P. mirabilis* is the fourth Gram-negative bacteria species after *E. coli*, *Klebsiella pneumoniae*, and *Enterobacter* spp. isolated from hospital-acquired BSIs ([@bib18]). BSIs are well-known cause of high mortality. We found that mortality rate of *P. mirabilis* BSIs was 28.9%. It is similar value to that obtained by [@bib7]. They found that mortality rate attributable to *P. mirabilis* BSIs was 33.0%.

[@bib12] showed that most cases of *P. mirabilis* bacteremia (18; 72.0%) have no documented sources and were recognized as primary bacteremia. In another seven (28.0%) cases, the urinary tract was confirmed to be the source of bacteremia. The opposite results were reported by [@bib18]. They detected primary bacteremia caused by *Proteus* spp. in 32.4% patients. The source of bacteria in secondary bacteremia was found mostly (35.1%) in the urinary tract and intra-abdominal cavity (21.6%) ([@bib1]). Infections of the urinary tract were admitted as the main source of BSIs also in the study by [@bib19]. They showed this phenomenon in BSIs caused by 19 (52.8%) multidrug resistant (MDR) and 28 (4.4%) non-MDR *P. mirabilis* strains.

Our data confirms the findings of [@bib18]. In most cases (58; 59.2%), the bacteremia caused by *P. mirabilis* was secondary due to the presence of these bacteria in other body sites, particularly in the urinary tract (27; 46.6%). In 14 (24.1%) patients, we found *P. mirabilis* in wound swabs. Wound infected by *P. mirabilis* was confirmed as the source of BSIs in the patient of the Traumatic Care Unit in India ([@bib7]).

*Proteus* spp. is inherently susceptible to co-trimoxazole (trimethoprim-sulfamethoxazole). In the present study we found that more than half (51.0%) of the *Proteus* spp. strains, isolated from patients with bacteremia, were resistant to co-trimoxazole. High resistance to cotrimoxazole was reported also in another paper ([@bib20]). Among 158 examined strains isolated from blood samples during longitudinal nationwide study from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program, the resistance of *P. mirabilis* to co-trimoxazole was found in 65.2% strains. Similar percentage (69.2%) of co-trimoxazole resistance was reported also for ESBLs-producing *P. mirabilis* strains isolated from blood samples ([@bib14]). In this study, we found that almost all ESBLs(+) strains (17; 94.4%) were non-susceptible to co-trimoxazole. Lower percentages of resistant strains were found in the study by [@bib19]: 33.3% among non-MDR, and 30.6% among MDR *P. mirabilis* strains involved in BSIs development.

ESBLs were found by [@bib1] in nine (24.3%) out of 37 *P. mirabilis* strains causing bacteremia from 2000 to 2009. In our study, we detected ESBLs in 18.4% *P. mirabilis* isolates causing bacteremia during the period evaluated. The highest number of ESBL-positive strains was found in 2016 (6; 33.3%). [@bib19] noted that ESBLs were confirmed in 36 (36.4%) out of 99 *P. mirabilis* strains causing BSIs. MDRs were recorded for 36 (36.6%) strains tested.

[@bib19] diagnosed *P. mirabilis* BSIs in 103 adult patients. The growth of the strains was inhibited by meropenem, amoxicillin with clavulanic acid, piperacillin with tazobactam, and amikacin. [@bib1] confirmed that most *P. mirabilis* isolates from BSIs were susceptible to piperacillin with tazobactam (98.3%) and amikacin (93.5%). In the study by [@bib20], 58.9--87.3% of *P. mirabilis* strains isolated from blood samples were susceptible to gentamicin and amikacin, respectively. This is in agreement with the present results. *Proteus* spp. strains examined in this study were mostly susceptible to piperacillin with tazobactam (95.3%) and amikacin (86.7%).

*Proteus* spp. strains were generally susceptible to ciprofloxacin (67.1--73.4% of the strains) ([@bib19]; [@bib20]). [@bib19] found that susceptibility to ciprofloxacin is rare among MDR strains and was showed only by three (8.3%) out of 36 strains. [@bib1] claim that a correlation between ciprofloxacin resistance and ESBLs production in *P. mirabilis* bacteremia may occur. This is in agreement with our results. We found significant differences in the susceptibility of ESBLs(+) and ESBLs(--) *Proteus* spp. strains to ciprofloxacin.

[@bib17] investigated the genetic similarity of *P. mirabilis* strains isolated from hospitalized patients. They confirmed identical DNA profiles of the isolates from blood and urine of the same patient. In the present study, we report that strains isolated from blood samples of 10 out of 11 patients were identical with isolates cultured from other clinical specimens. The same strains were isolated from various specimens also a few weeks after the bacteremia, that it is because of the survival of *Proteus* spp. strains despite the antibiotic treatment. The decrease in the effectiveness of antibiotic treatment may be related to the biofilm forming ability.

In most cases we observed that strains from clinical samples collected from infections related to biomaterials were able to form stronger biofilms than identical strains from other samples collected from these patients. The presence of biomaterials in body sites probably promotes biofilm formation, which is in agreement with the results obtained by [@bib14] and [@bib4]. We also reported that isolates collected from chronic wounds prior to bacteremia were able to form stronger biofilms than isolates cultured from blood samples.

Conclusions {#sec6}
===========

In most cases bacteremia caused by *Proteus* spp. was secondary to urinary tract infection.

Most of the strains isolated from *Proteus* spp. BSIs were susceptible to piperacillin with tazobactam, third generation of cephalosporins, and amikacin.

Elderly patients have a higher risk of mortality in consequence of *Proteus* spp. BSI.

Most strains isolated from blood samples were identical to isolates cultured from other clinical specimens of the same patient.
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